A new study lacked significant results, but when combined with additional studies, the prevention of cardiovascular events ...

Teamwork and systematic follow-up strategies among interdisciplinary staff can improve patient engagement and appointment ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

Two years after percutaneous coronary intervention, people at risk of a cardiac event had better outcomes with clopidogrel ...

Same-day discharge after joint replacement surgery is feasible in patients with a history of atrial fibrillation (AF), ...

The use of ketamine, midazolam, lorazepam, droperidol, and haloperidol was also assessed. Children who interacted with ...

Implementation of the ERAS program delivers better patient outcomes, achieves shorter lengths of stay, and saves money.

Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

Echocardiography is independently associated with survival time and readmission rates in patients with type 2 diabetes.